7 participants
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2023-09-21
- Start Date:
- 2017-10-27
- Completion:
- 2022-11-21
Conditions
- High Risk Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- BIOLOGICAL